Abstract
In this study, we investigated the in vitro activity of SCH-56592 (SCH), a new triazole antifungal agent. We compared the activity of SCH with those of itraconazole (ITZ) and amphotericin B (AB) against 60 clinical isolates of Aspergillus spp. by using a microtiter format. Incubation was done at 37 degrees C for 48 h, and MIC endpoints (no growth) were read visually. The medium used for all of the drugs was RPMI 1640 buffered with morpholinepropanesulfonic acid (MOPS) and supplemented with 2% glucose. MICs and minimum fungicidal concentrations (MFCs; killing of > or = 99.99%) were measured for all isolates. The geometric mean (GM) MICs and ranges (in micrograms per milliliter) were as follows: SCH, 0.09 and < or = 0.01 to 1; ITZ, 0.25 and 0.06 to 32; AB, 1.46 and 0.25 to 32. Aspergillus terreus (n = 7) was markedly more susceptible to SCH (GM, 0.05 microg/ml) and ITZ (GM, 0.07 microg/ml) than to AB (GM, 8.8 microg/ml). For all isolates, the GM MFCs and ranges (in micrograms per milliliter) were as follows: SCH, 3.64 and 0.125 to 16; ITZ, 15.09 and 0.125 to 32; AB, 10.3 and 1 to 32. In the drug concentration range tested, 71, 32, and 64% of the isolates against which SCH, ITZ, and AB, respectively, were tested were killed. A reproducibility study was performed with 20% of the isolates; for 11 of the 12 isolates retested, the MIC was the same or within 1 well of the original MIC of each drug. Therefore, in vitro mould testing of SCH is feasible and reproducible. SCH was found to be very active against all species of Aspergillus and at lower concentrations than either ITZ or AB.
Full Text
The Full Text of this article is available as a PDF (270.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Denning D. W., Follansbee S. E., Scolaro M., Norris S., Edelstein H., Stevens D. A. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991 Mar 7;324(10):654–662. doi: 10.1056/NEJM199103073241003. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Hanson L. H., Perlman A. M., Stevens D. A. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis. 1992 Jan;15(1):21–34. doi: 10.1016/0732-8893(92)90053-v. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Lee J. Y., Hostetler J. S., Pappas P., Kauffman C. A., Dewsnup D. H., Galgiani J. N., Graybill J. R., Sugar A. M., Catanzaro A. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med. 1994 Aug;97(2):135–144. doi: 10.1016/0002-9343(94)90023-x. [DOI] [PubMed] [Google Scholar]
- Denning D. W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996 Sep;23(3):608–615. doi: 10.1093/clinids/23.3.608. [DOI] [PubMed] [Google Scholar]
- Espinel-Ingroff A., Bartlett M., Bowden R., Chin N. X., Cooper C., Jr, Fothergill A., McGinnis M. R., Menezes P., Messer S. A., Nelson P. W. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol. 1997 Jan;35(1):139–143. doi: 10.1128/jcm.35.1.139-143.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Espinel-Ingroff A., Dawson K., Pfaller M., Anaissie E., Breslin B., Dixon D., Fothergill A., Paetznick V., Peter J., Rinaldi M. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995 Feb;39(2):314–319. doi: 10.1128/aac.39.2.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Galgiani J. N., Lewis M. L. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1997 Jan;41(1):180–183. doi: 10.1128/aac.41.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Groll A. H., Shah P. M., Mentzel C., Schneider M., Just-Nuebling G., Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996 Jul;33(1):23–32. doi: 10.1016/s0163-4453(96)92700-0. [DOI] [PubMed] [Google Scholar]
- Ng T. T., Robson G. D., Denning D. W. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology. 1994 Sep;140(Pt 9):2475–2479. doi: 10.1099/13500872-140-9-2475. [DOI] [PubMed] [Google Scholar]
- Pfaller M. A., Messer S., Jones R. N. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1997 Feb;41(2):233–235. doi: 10.1128/aac.41.2.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roilides E., Holmes A., Blake C., Venzon D., Pizzo P. A., Walsh T. J. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis. 1994 Oct;170(4):894–899. doi: 10.1093/infdis/170.4.894. [DOI] [PubMed] [Google Scholar]
- Roilides E., Sein T., Holmes A., Chanock S., Blake C., Pizzo P. A., Walsh T. J. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis. 1995 Oct;172(4):1028–1034. doi: 10.1093/infdis/172.4.1028. [DOI] [PubMed] [Google Scholar]